Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

319.48USD
20 Nov 2018
Change (% chg)

-- (--)
Prev Close
$319.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
545,989
52-wk High
$388.67
52-wk Low
$249.24

Select another date:

Thu, Oct 25 2018

Photo

Eisai, Biogen Alzheimer's data fails to convince skeptics

Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

UPDATE 2-Eisai, Biogen Alzheimer's data fails to convince skeptics

Oct 25 Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

UPDATE 1-Biogen shares slip after Alzheimer's data fails to convince

Oct 25 Biogen Inc and partner Eisai Co Ltd said on Thursday the highest dose of its experimental Alzheimer's drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data.

Biogen/Eisai Alzheimer's data suggests treatment effect related to drug

Oct 25 Biogen and partner Eisai Co Ltd said data from their experimental Alzheimer's drug suggested that the treatment effect for the highest dose was related to the drug, and not to an imbalance of patients in the treatment groups.

Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

UPDATE 1-Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

Oct 24 A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

Oct 24 A U.S. appeals court on Wednesday upheld a ruling that patents owned by Biogen Inc covering its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

Biogen's Spinraza drives third-quarter profit beat

Biogen Inc on Tuesday handily beat Wall Street expectations for third quarter profit, led by strong demand for its new blockbuster muscle disease treatment Spinraza.

UPDATE 3-Biogen's Spinraza drives third-quarter profit beat

* MS drug Tecfidera misses analyst estimates (Adds CEO, analyst comment, share movement, Spinraza details from conference call)

Select another date: